Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors
Therapeutic Advances in Cardiovascular Disease · 2012-12 · 6 (6) · 229-236
DOI: 10.1177/1753944712464102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 09.10.2012. Verfasst von Ravi K Sureddi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot #532, Little Roc…. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Atrial fibrillation (AF) often develops in patients with multiple myeloma following autologous stem cell transplantation (ASCT), but the exact incidence of, and the risk factors for AF have not been described. In this study, we sought to determine the incidence of AF in patients with multiple myeloma undergoing ASCT.
Methods
Patients who received ASCT for multiple myeloma between January 2000 and December 2009 were identified using the ICD-9 codes for multiple myeloma and ASCT, and formed the basis of this report.
Results
The study included 278 patients (mean age, 63 ± 9.5 years). A total of 75 (27%) patients developed AF at a mean duration of 14.8 days following ASCT. On multiple regression analysis, baseline renal dysfunction (odds ratio 15.2 [confidence interval 5.08–45.6]), left ventricular systolic dysfunction (9.55 [2.78–32.79]), dilated left atrium on echocardiogram (4.97 [1.8–13.78]), and hypertension (3.6 [1.36–9.52]) were significantly associated with the development of AF after ASCT. The presence of light-chain secretion (0.21 [0.07–0.6]) was associated with a lower incidence of AF. Age, gender, and race were not significantly associated with the development of AF after ASCT.
Conclusions
AF is very frequent in patients with multiple myeloma when they receive ASCT. The presence of abnormal renal function, left ventricular systolic dysfunction, dilated left atrium, or hypertension at baseline identifies patients at high risk of developing AF following ASCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot #532, Little Rock, AR 72211, USA. rksureddi@gmail.com
Zitieren
APA
Sureddi, R. K., Amani, F., Hebbar, P., Williams, D. K., Leonardi, M., Paydak, H., & Mehta, J. L. (2012). Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors. Therapeutic Advances in Cardiovascular Disease, 6(6), 229-236. https://doi.org/10.1177/1753944712464102
Vancouver
Sureddi RK, Amani F, Hebbar P, Williams DK, Leonardi M, Paydak H, et al. Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors. Therapeutic Advances in Cardiovascular Disease. 2012;6(6):229-236. doi:10.1177/1753944712464102
BibTeX
@article{Sureddi2012,
author = {Sureddi, Ravi K and Amani, Fariba and Hebbar, Prabhat and Williams, David K and Leonardi, Marino and Paydak, Hakan and Mehta, J L},
title = {Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors},
journal = {Therapeutic Advances in Cardiovascular Disease},
year = {2012},
volume = {6},
number = {6},
pages = {229--236},
doi = {10.1177/1753944712464102}
}
EUVIMED